Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Earnings for Enzo Biochem, Inc. (ENZ)
Earnings in 2024 (TTM): $-9,817,000
According to Enzo Biochem, Inc.'s latest financial reports the company's current earnings (TTM) are $-9,817,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Enzo Biochem, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-9,817,000 | $-26,078,000 |
| 2023 | $-25,022,000 | $20.29 M |
| 2022 | $-18,261,000 | $-22,578,000 |
| 2021 | $7.88 M | $3.43 M |
| 2020 | $-28,520,000 | $-33,890,000 |
| 2019 | $2.49 M | $-98,781,000 |
| 2018 | $-11,418,000 | $-10,321,000 |
| 2017 | $-2,422,000 | $-2,504,000 |
| 2016 | $46.52 M | $45.29 M |
| 2015 | $-2,292,000 | $-2,285,000 |
| 2014 | $-9,905,000 | $-9,977,000 |
| 2013 | $-18,949,000 | $-18,237,000 |
| 2012 | $-40,921,000 | $-39,269,000 |
| 2011 | $-12,823,000 | $-12,960,000 |
| 2010 | $-22,261,000 | $-22,233,000 |
| 2009 | $-23,477,000 | $-23,564,000 |
| 2008 | $-10,892,000 | $-10,653,000 |
| 2007 | $-13,175,000 | $-13,260,000 |
| 2006 | $-17,009,000 | $-15,667,000 |
| 2005 | $5.22 M | $3 M |
| 2004 | $-11,079,700 | $-6,231,600 |
| 2003 | $5.73 M | $3.84 M |
| 2002 | $10.34 M | $6.92 M |
| 2001 | $12.23 M | $6.81 M |
| 2000 | $7.67 M | $6.62 M |
| 1999 | $5.4 M | $6.5 M |
| 1998 | $2.6 M | $3.4 M |
| 1997 | $1.6 M | $1.5 M |
| 1996 | $-7,500,000 | $-7,700,000 |
| 1995 | $9.7 M | $5.6 M |
| 1994 | $2.2 M | $5.3 M |
| 1993 | $-6,300,000 | $-6,900,000 |
| 1992 | $-1,100,000 | $-600,000 |
| 1991 | $-2,600,000 | $-10,800,000 |
| 1990 | $-3,900,000 | $-4,100,000 |
| 1989 | $-4,000,000 | $-4,100,000 |
| 1988 | $100 K | $-3,500,000 |
| 1987 | $-3,600,000 | $-1,600,000 |
| 1986 | $2.1 M | $1.5 M |